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administration were examined by vaccine and type of setting including 
physician offices, pharmacies, and other medical settings (e.g., 
inpatient/outpatient hospitals, emergency rooms). RESULTS: Of those receiving 
ZOSTAVAX®, PNEUMOVAX® 23 and influenza vaccines, 25%, 1%, and 7%, 
respectively, received it at a pharmacy. Compared to other US regions, 
pharmacy-based vaccination for these 3 vaccines was generally higher in the 
western and southern regions. Overall, the mean (SD) paid amounts per enrollee 
per vaccine administration at the physician offices, pharmacies, and other 
medical settings were as follows: ZOSTAVAX® $208.7 (42.1), $168.5 (15.7), and 
$209.5 (50.8), respectively (p<0.05); PNEUMOVAX® 23 $65.6 (27.5), $55.0 (9.7), and 
$72.1 (50.0), respectively (p<0.05); and influenza $29.3 (15.3), $21.6 (6.6), and $24.2 
(13.1), respectively (p<0.05). The mean paid amounts also differed by geographic 
regions and type of health plan, with costs usually lower for the vaccinations 
given at the pharmacies. CONCLUSIONS: The average direct costs per adult 
vaccination were lower in pharmacies, compared to physician offices and other 
medical settings by 16-26% and 11-20 %, respectively. These results were mostly 
consistent across geographic regions and types of health plans. These data may 
help payer and policymaker understand economic value of adult vaccination in 
different settings, especially in pharmacies.  
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OBJECTIVES: Currently, diagnosis of a bloodstream infection relies on culture-
based methods and takes 2-3 days. The development of a rapid diagnostic tool 
has been deemed a high priority by the Infectious Disease Society of America. 
Available rapid tests are limited by the need to target specific pathogens. Rapid 
tests for universal detection of bacterial or fungal pathogens are in development. 
Commercialization of such a test will allow physicians to make rapid decisions, 
avoid unnecessary hospitalization, and decrease morbidity. No economic 
analyses have yet assessed the potential medical cost impacts of such a test. 
METHODS: We performed a decision tree analysis to estimate the potential 
medical cost consequences of a rapid test to detect bloodstream infection, using 
data from published literature and expert opinion. We considered potential 
impacts in the areas of diagnostic testing, prevention of diseases, and reduction 
in hospital admissions. Medicare pricing schedules were used, analyses were 
conducted from the health care payer perspective, and a base case cost of 
$20/test was used. RESULTS: Our model demonstrates that with population-wide 
implementation, the annual U.S. medical cost savings associated with decreased 
clinical diagnostic testing, reduced antimicrobial use, disease prevention, 
avoidance of hospitalization, and reduction in hospital length of stay could be 
$0.2, $0.3, $1.2, $1.1 and $1.6 billion, respectively. An increase in diagnostic 
testing cost to $40, $50 and $60/test lowers net savings by 3.6%, 5.4% and 7.2%, 
respectively. A tripling of the testing cost still allows for net savings of >$3.6 
billion to the health care system. CONCLUSIONS: Our analysis suggests that 
routine hospital-based use of a rapid diagnostic test for bacterial and fungal 
bloodstream infections would result in substantial savings to U.S. health care 
payers. If such a test were available, and its negative predictive value for 
bloodstream infection were very high, it would likely become a dominant 
diagnostic strategy.  
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OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C 
(HCV) in Germany (62% genotype 1). HCV is one of the leading causes for chronic 
liver disease. Experts have estimated that about 27% of end-stage cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. Although HCV is 
associated with high costs, reliable data are scarce in Germany. Aim of the study 
was to assess the costs for treating chronically infected HCV patients in routine 
care. METHODS: We conducted a retrospective multicenter observational study. 
Design was approved by an ethics committee and patients were asked for their 
informed consent. Health care utilization was extracted from doctor files in six 
medical centers. Costs were calculated using official fee-scales and statistics. 
Societal perspective was taken. RESULTS: In total, 315 patients were analyzed. 
The mean age was 49.4 years, 57.5% were male and 67.9% had a genotype-1 
infection. Most common routes of transmission were injection drug use (39.0%) 
and infection through blood products (15.9%). In 41.3% of patients route of 
transmission was unknown. The average total costs were €19,147 including 
ambulatory care (€1,686), pharmaceuticals (€14,875), inpatient care (€1,293) and 
sick leave (€1,293). Cost differences were observed between patients groups (mild 
HCV, moderate HCV and compensated cirrhosis, decompensated cirrhosis). 
Patients receiving a 16-week treatment had average total costs of €8,230. A 24-
week treatment resulted in €13,674, 48-week treatment in €25,396 and 72-week 
treatment in €41,175. In nearly 30% of patients treatment duration did not 
correspond to official recommendations. CONCLUSIONS: Treatment of HCV 
patients is associated with high costs mainly affected by length of antiviral 
therapy. It is inevitable to follow current guidelines and monitor patients closely 
in order to avoid unnecessary costs. The analysis is the basis for implementing 
new therapies which started with the introduction of protease inhibitors in 2011.  
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OBJECTIVES: To determine the economic and health care resource burden of 
seasonal Influenza, in the UK, using linked, individual patient, hospital and 
family doctor records, including mortality stratified by; age, risk factors and 
complications. METHODS: A cross-sectional observational study design was 
carried out using data derived from linked GPRD, between January 2001 and 
March 2009. Subjects included were; all those with family doctor coded episodes 
of care for acute respiratory events related to infection (influenza, upper and 
lower respiratory tract infections (LRTI), and Influenza like illness (ILI)). Analysis 
was stratified by age and ‘at risk’ conditions recommended for influenza 
vaccination in the UK. UK 2011 published reference costs were used. RESULTS: 
156,193 influenza episodes were recorded during the study period, with mean 
age 42.7 years (SD 20.3). Of these 1,592 (1.0%) were hospitalised with mean length 
of stay of 7 days; 1,182 (0.8%) deaths occurred within 28 days. The risk of 
hospitalisation and mortality was lower in those vaccinated; odds ratio 0.59 and 
0.78 respectively. Cardiovascular complications, COPD and LRTI were associated 
with the largest number of deaths. Highest mortality rates were in patients 
≥65yrs. Costs escalate with complicated influenza episodes (average cost 
influenza £2,264/hospitalisation vs. complicated influenza £9,384/hospitalisation) 
and age (≤64yrs £6,166/hospitalisation; ≥65yrs £11,674/hospitalisation). 
Respiratory and chronic heart disease risk status had highest overall costs, but 
CNS risk had highest cost per episode (£15,198/hospitalisation). CONCLUSIONS: 
This study, the first of its kind in the UK, demonstrates that seasonal influenza, 
even at a time of low overall activity, is associated with a substantial burden of 
illness, which is preventable by vaccination. This study is likely to underestimate 
the true impact of influenza due to; only capturing individuals who visit a 
physician, because most affected individuals self-diagnose, and the 
incompleteness and coding errors inherent within administrative databases.  
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OBJECTIVES: To evaluate health care utilization and costs of patients with 
aspergillosis within a large, commercially-insured population in the US. 
METHODS: Adults ≥18 years with at least one inpatient, emergency room, or 
outpatient medical claim with an aspergillosis diagnosis (ICD-9-CM 117.3 or 
484.6) between July 1, 2004 to March 1, 2011 and ≥6 months of pre-index and ≥1 
month of continuous post-index health plan and pharmacy benefit enrollment 
were identified from the MarketScan Research Databases. Patients with a diagnosis 
of aspergillosis in the pre-index period were excluded. Aspergillosis cases were 
propensity score-matched to a sample of controls without aspergillosis.. A 
general linear model was used to estimate total costs which were adjusted by 
the probability of remaining in the study to a given point in time (e.g., 90, 180, 
365 days). Incremental costs were calculated between cohorts and a bootstrap 
procedure was used to produce corresponding variation and 95% confidence 
interval estimates. RESULTS: Patients with aspergillosis (N= 5499; mean age: 57.8 
years; 48.6% female; 39.1% with cancer; 34% with an index diagnosis in the 
inpatient setting) were matched to 5499 controls (mean age: 58.3 years; 48.4% 
female; 40.3% with cancer). Aspergillosis cases had a higher proportion of 
hospitalizations and a longer average length of stay, as well as a higher rate of ER 
use and monthly outpatient office visits, laboratory tests, and outpatient 
prescriptions during follow-up than controls. All contrasts were significant at 
p<0.001. The estimated mean incremental costs of patients with aspergillosis, 
adjusted for the probability of remaining in the study for a given duration of 
follow-up time, were $22,732.99, $19,620.51 and $17,870.09 for durations of 90, 
180, and 365 days, respectively. CONCLUSIONS: The economic burden of 
aspergillosis is substantial. Patients with aspergillosis utilize significantly more 
health care and thus incur greater health care costs than do similar patients 
without aspergillosis.  
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OBJECTIVES: Low uptake of routinely recommended adult immunizations is a 
public health concern. Using data from peer-reviewed literature, we developed a 
customizable model to estimate the human and economic burden caused by four 
major adult vaccine-preventable diseases (VPD) in the United States and for each 
US state individually in 2010. METHODS: Three primary estimates were 
developed to populate the model: 1) estimated number of cases per year based 
on 2010 US Census population data and published incidence rates; 2) estimated 
direct medical costs of a single case; and 3) estimated indirect medical costs 
related to morbidity/lost productivity. Four major adult VPDs were examined: 1) 
influenza; 2) pneumococcal disease (both invasive disease and pneumonia); 3) 
herpes zoster; and 4) pertussis. RESULTS: Estimated US annual cost for the four 
adult VPDs was 15.1 billion (B) (10.4B for age ≥50). Among adults indicated for 
vaccination against the four VPDs, influenza (≥18yrs), pneumococcal disease 
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(≥50yrs), herpes zoster (≥50yrs), and pertussis (≥18yrs) made up 51%, 30%, 16%, 
and 3% of the cost, respectively. Among those aged ≥50 years, influenza, 
pneumococcal disease, herpes zoster, and pertussis made up 31%, 44%, 24%, and 
1% of the cost, respectively. Most (82%) pneumococcal costs stemmed from non-
bacteremic pneumococcal pneumonia (NPP). Direct medical costs accounted for 
91% of total pneumococcal burden, but only 27%, 28%, and 42% of total economic 
burden due to influenza, herpese zoster, and pertussis, respectively. Sensitivity 
analysis revealed that estimated influenza rates and costs per case, NPP 
incidence and directs costs, and herpes zoster incidence rates and indirect costs 
impacted the model most. CONCLUSIONS: Cost attributable to adult VPD in the 
United States is substantial. Broadening adult immunization efforts beyond 
influenza only may help reduce the economic burden of adult VPD, and a 
pneumococcal vaccination effort, primarily focused on reducing NPP, may be a 
logical place to start.  
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OBJECTIVES: To determine the epidemiologic and economic burdens  
of tuberculosis (TB) in Asia. METHODS: A systematically review of primary 
studies in Asia was conducted. We searched MEDLINE, PUBMED, EMBASE, 
Science Direct, CNKI from January 1, 2000 to July 15, 2012; and websites of 
relevant countries and international organizations. RESULTS: TB prevalence, 
incidence and mortality in the region have declined since 1990 and status relate 
to the economy of the country. In 2010, there were 8.8 million incident cases of 
TB (128/100000 population). Most of the cases occurred in Asia (59%) and Africa 
(26%). India and China accounted for 40% of new and relapse TB cases. In 2006, 
TB caused India to lose a 23.7 billion US$. The mean direct cost was US$34.9  
and mean indirect cost was $526.9. The total cost per patient was $562.7. In 
China, low income patients paid $149 to $724 for medical costs for a treatment 
course (42% to 119% of annual household income). In Philippines, the economic 
losses totaled PhP8 billion (US$145 million) and costs of treating all cases 
requires PhP475–1625 million (US$8–29 million) annually. In Cambodia, TB is the 
second largest cause of mortality. Monthly household costs were US$124/ 
patients ($135 for TB-HIV patients and $260 for resistant-TB patients); the 
average monthly income in Cambodia is $168. In Tajikistan, Patients and their 
households faced mean expenditures of US$ 396; (median US$ 282) related to a 
TB episode. CONCLUSIONS: Although most countries in Asia have done many 
efforts on TB control, the absolute number of patient is large that more efforts 
need to take to achieve the goal of 50% reduction in 2015 from 1990 set by WHO. 
More researches are recommended to study the economic burden in specific 
countries.  
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OBJECTIVES: To describe the cost of outbreak of meningococcal disease in 
Cartagena - Colombia. METHODS: The cost of meningococcal disease outbreak 
from February 21st thru March 21st2012, were described. The suspected cases 
were detected in the Children´s Hospital Napoleon Franco Pareja, House of the 
Child (HC) and they were reported to the Departamento Administrativo Distrital 
de Salud (DADIS, for acronym in Spanish). We ran an active surveillance program 
in the neighborhood cases. The investigation costs of the outbreak control, 
surveillance and health care cost were estimated. RESULTS: During 
meningococcal disease outbreak and following 1 month of active surveillance, a 
total of 6 cases were detected; from which one suspected case, one probable case 
and four were confirmed cases. The average patient age was 4.6 years. 50% of the 
cases died, 33% of the cases had meningitis, meningococcemia and myocarditis. 
66% of the cases had culture specimen positive with Neisseria meningitidis. 5/6 
cases (83%) had RT-PCR positive with Neisseria meningitidis. All N. meningitidiswere 
serogroup B. 50 doses of ceftriaxone were administered as prophylaxis. DADIS 
did not recommend meningococcal vaccination and the proper vaccine was not 
available at the time. The costs of meningococcal outbreak were estimated as 
follows: Cost of control of the outbreak (US $ 735), disease surveillance phase (US 
$ 3,935) and health care cost was US $ 4.670. CONCLUSIONS: All cases were 
caused by N. meningitidis serogroup B. The absence of vaccination involves lower 
costs in control of the outbreak.  
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OBJECTIVES: Patients with COPD are at increased risk for lung infections, such as 
pneumonia. However, few studies have evaluated the impact of pneumonia on 
health care resource utilization (HCRU) and cost in this population. The objective 
of this study is to estimate HCRU and cost in COPD patients with newly acquired 
pneumonia, compared to those without pneumonia. METHODS: A retrospective 
analysis using MarketScan® Commercial Claims and Encounters and Medicare 
Supplemental Databases was conducted. COPD patients with and without newly 
diagnosed pneumonia between January 1, 2005 and September 30, 2010 were 
identified. Propensity score matching was used to create a one-to-one matched 
cohort. Patient demographics, comorbidities measured by Charleston 
Comorbidity Index (CCI), and medication use were evaluated before and after 
matching. HCRU, including the number of hospitalizations, emergency room 
(ER), and outpatient visits, length of hospital stay (LOS), and associated health 
care costs were assessed during the 12-month follow up. Two-part models and 
gamma regression models were conducted to compare costs between groups 
after matching. RESULTS: In the baseline cohort of 520,008 patients, newly 
acquired pneumonia patients were older (mean age: 70 vs. 63 years) and sicker 
(CCI: 3.25 vs. 2.67). After matching, no baseline covariates were statistically 
different between groups. In the matched cohort of 168,260 patients, one-year 
mean HCRU after pneumonia onset was significantly higher (all p<0.0001) for 
inpatient visits (1.2 vs. 0.29), ER visits (1.9 vs. 0.68), outpatient visits (34.97 vs. 
23.1) and LOS (7.3 vs. 1.3 days) than the control cohort. Estimated one-year mean 
costs were higher in the pneumonia cohort with differences in: inpatient costs 
$14,353 (95% CI: $14,037, $14,690), outpatient costs $6,891 ($6,706, $7,075), 
prescription drug costs $1,104 ($1,054, $1,152) and total costs $23362 ($22,969, 
$23,787). CONCLUSIONS: Our study demonstrates elevated HCRU and costs in 
COPD patients after acquiring pneumonia.  
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OBJECTIVES: The cost of antibiotics is always an area of concern in treating RTI. 
The purpose of the current study was to determine the contribution of costs of 
antibiotics on the overall prescription costs in paediatric patients. METHODS: 
The study was carried out at a pediatric outpatient setting where data of 688 
patients, below 18 years of age, was captured over a period of one year from the 
“Wise-kid” software. RESULTS: RTI was most common in the age group of 1-3 Y 
(32%) and 3-6 Y (30%). It affects the patients mostly in winter (35%) followed by 
autumn (25%). Antibiotic prescribed from NLEM-2011 were found to be 92%. All 
the antibiotics were prescribed by oral route with brand name only. Percentage 
of encounters with antibiotics in RTI, were highest in acute otitis media (AOM, 
89%), followed by lower respiratory tract illness (LRTI, 76%), tonsillitis (71%), 
upper respiratory tract infection (URTI) + bronchospasm (17%), URTI (13%) and 
influenza like illness (ILI, 13%). The average cost of treatment was maximum for 
AOM (INR186±7; 1USD=approx INR55) followed by LRTI, ILI, URTI (181±11, 125±6 
& 120±2, respectively in INR). While the average cost spent on antibiotic 
treatment was INR 82±8. Of total cost, 17% was spent on the utilization of 
antibiotics.The order for cost spent on use of different class of drug were cold & 
cough combinations (37%) > NSAIDs (9%) > nasal drops. The contribution of 
antiasthmatics, antihistamines & antibiotics was found to be 6% each. Among 
antibiotics, maximum cost were spent on the use of amoxicillin+clavulanic acid 
combination (66%) followed by the cost spent on the prescribing of azithromycin, 
cefpodoxime, clarithromycin, cephalexin & ofloxacin (24%, 4%, 4%, 1.5% & 1% 
respectively). CONCLUSIONS: The results indicate that less than 20% costs were 
spent on antibiotics for the treatment of RTI. These results build the evidence for 
the cost of treating RTI in children.  
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OBJECTIVES: To evaluate the occurrence and associated health care utilization 
and costs of potential adverse events (AEs) associated with outpatient 
voriconazole use among patients with aspergillosis. METHODS: Commercially-
insured adults aged ≥18 years with at least one medical claim with a diagnosis  
of aspergillosis (ICD-9-CM 117.3 or 484.6) between July 1, 2004-March 1, 2011 and 
outpatient voriconazole treatment on or after the index diagnosis were identified 
from the MarketScan Research Databases. Patients were required to have ≥6 
months of pre-index and ≥1 month of post-index health plan and pharmacy 
benefit enrollment. Patients with an aspergillosis diagnosis in the pre-index 
period were excluded. Potential AEs, as indicated in the package insert  
for voriconazole, were identified via diagnosis codes and were evaluated for 
periods during active treatment plus 7 days. AE-related monitoring , such as 
organ function tests and visits with ophthalmologists, were also evaluated. Total 
all-cause costs and potential AE-related costs were calculated. RESULTS: A total 
of 1511 patients treated with voriconazole were identified. The most common 
conditions observed during active treatment with voriconazole plus 7 days were 
fever (15.1%), tachycardia (12.2%), acute kidney failure (8.9%), and 
nausea/vomiting (8.4%). AE-related inpatient admissions and outpatient 
physician office visits were observed for 19.9% and 40.8% of patients, 
respectively. Outpatient AE-related organ function testing, aspergillosis-related 
laboratory tests, including therapeutic drug monitoring, and at least one office 
visit with an ophthalmologist, was observed among 16.3%, 34.5%, 18.1%  
of patients, respectively. Average total, aspergillosis-related costs during follow-
up of patients treated with voriconazole were $35,968 ± $68,590. Average total 
costs associated with adverse events and adverse event monitoring were $3,772 
± $30,057 or 10.5% of total average costs. CONCLUSIONS: Conditions suggestive 
of AEs associated with voriconazole occurred frequently, and were associated 
